<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01379300</url>
  </required_header>
  <id_info>
    <org_study_id>0000-216</org_study_id>
    <nct_id>NCT01379300</nct_id>
  </id_info>
  <brief_title>A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)</brief_title>
  <official_title>A Randomized Clinical Trial to Validate Novel Biomarker Approaches After Single Doses of Anticoagulants in Healthy Young Male Subjects and in Healthy Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to investigate biomarkers after single oral doses of the anticoagulant agents&#xD;
      dabigatran etexilate and rivaroxaban in healthy young male subjects and in healthy elderly&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endogenous thrombin potential by Thrombin Generation Assay (TGA)-2a assay</measure>
    <time_frame>From up to 2 hours pre-dose to up to 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of fibrin degradation product (D-dimer)</measure>
    <time_frame>From up to 2 hours pre-dose to up to 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of fibrinopeptide A (FPA)</measure>
    <time_frame>From up to 2 hours pre-dose to up to 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of prothrombin split products (F1+2)</measure>
    <time_frame>From up to 2 hours pre-dose to up to 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of thrombin-antithrombin complex (TAT)</measure>
    <time_frame>From up to 2 hours pre-dose to up to 24 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>Dabigatran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 150-mg dose of dabigatran etexilate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 20-mg dose of rivaroxaban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No study drug will be administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran etexilate</intervention_name>
    <description>dabigatran etexilate, orally, as 2 x 75-mg capsules (150 mg), single administration</description>
    <arm_group_label>Dabigatran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivaroxaban</intervention_name>
    <description>rivaroxaban, orally, as 2 x 10-mg tablets (20 mg), single administration</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for non-hemophilia participants:&#xD;
&#xD;
        Panel A&#xD;
&#xD;
        - Male or female between 65 to 85 years of age&#xD;
&#xD;
        Panel B&#xD;
&#xD;
        - Male between 18 to 45 years of age&#xD;
&#xD;
        Both Panels&#xD;
&#xD;
          -  Weight of ≥50 kg and ≤110 kg&#xD;
&#xD;
          -  In good health&#xD;
&#xD;
          -  No clinically significant abnormality on electrocardiogram (ECG)&#xD;
&#xD;
          -  Nonsmoker and/or has not used nicotine or nicotine-containing products for at least&#xD;
             approximately 6 months&#xD;
&#xD;
        Exclusion criteria for non-hemophilia participants:&#xD;
&#xD;
          -  History of stroke, chronic seizures, or major neurological disorder&#xD;
&#xD;
          -  History of clinically significant endocrine, gastrointestinal (including peptic ulcer&#xD;
             disease), cardiovascular, hematological, hepatic, immunological, renal, respiratory,&#xD;
             or genitourinary abnormalities or diseases&#xD;
&#xD;
          -  History of malignant neoplastic disease, with the exception of adequately treated&#xD;
             non-melanomatous skin carcinoma or other malignancies that have been successfully&#xD;
             treated ≥10 years prior to the study&#xD;
&#xD;
          -  History of a thrombotic or platelet-related disorder including prior deep venous&#xD;
             thrombosis or pulmonary embolus&#xD;
&#xD;
          -  Use of warfarin, coumadin, heparin, aspirin, dabigatran etexilate, rivaroxaban or&#xD;
             dipyridamole within 2 weeks&#xD;
&#xD;
          -  History of poor wound healing&#xD;
&#xD;
          -  Unable to refrain from or anticipates the use of any medication, including aspirin and&#xD;
             aspirin-containing products, all non-steroidal anti-inflammatory drug&#xD;
             (NSAID)-containing products (including pain, cold and allergy products, etc.) and&#xD;
             including prescription and non-prescription drugs or herbal remedies (such as St.&#xD;
             John's Wort [Hypericum perforatum]) beginning approximately 2 weeks (or 5 half-lives)&#xD;
             prior to initiation of the treatment periods, throughout the study until the&#xD;
             post-study visit&#xD;
&#xD;
          -  Consumption of excessive amounts of alcohol, defined as greater than 3 glasses of&#xD;
             alcoholic beverages (1 glass is approximately equivalent to: beer [284 mL/10 ounces],&#xD;
             wine [125 mL/4 ounces], or distilled spirits [25 mL/1 ounce]) per day&#xD;
&#xD;
          -  Consumption of excessive amounts, defined as greater than 6 servings (1 serving is&#xD;
             approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or other&#xD;
             caffeinated beverages per day&#xD;
&#xD;
          -  Major surgery, donation or loss of 1 unit of blood (approximately 500 mL) or&#xD;
             participation in another investigational study within 4 weeks&#xD;
&#xD;
          -  History of significant multiple and/or severe allergies (including latex allergy), or&#xD;
             an anaphylactic reaction or significant intolerability to prescription or&#xD;
             non-prescription drugs or food, including dabigatran etexilate and rivaroxaban&#xD;
&#xD;
          -  Current regular user (including illicit drugs or has a history of drug [including&#xD;
             alcohol] abuse within approximately 6 months&#xD;
&#xD;
          -  History (including family history if hereditary) or symptoms of clinically relevant&#xD;
             bleeding disorder&#xD;
&#xD;
          -  Organic lesion at risk of bleeding (e.g., aneurysm, cavernous hemangioma,&#xD;
             arterio-venous malformation)&#xD;
&#xD;
          -  History of frequent epistaxis or has recurrent or active gingivitis or hemorrhoids&#xD;
&#xD;
        Inclusion criteria for hemophilia participants:&#xD;
&#xD;
          -  Male with diagnosis of hemophilia B between 18 to 64 years of age&#xD;
&#xD;
          -  Weight of ≥110 lbs and ≤300 lbs&#xD;
&#xD;
          -  Has not received clotting factor in the 7 days prior to blood sampling&#xD;
&#xD;
          -  No active bleeding event&#xD;
&#xD;
          -  No procedure or surgery in the past 8 weeks&#xD;
&#xD;
          -  Judged to be in good health based on medical history&#xD;
&#xD;
          -  Has not smoked more than 2 cigarettes per day for at least approximately 1 week prior;&#xD;
             has not smoked a pipe or cigar or chewed tobacco for at least 3 days prior&#xD;
&#xD;
          -  Can refrain from the use of all NSAIDs (e.g., Advil, Aleve, aspirin), all&#xD;
             NSAID-containing products (including pain, cold, and allergy products, etc.), herbal&#xD;
             meds or drugs for 7 days prior to the date of study procedure&#xD;
&#xD;
        Exclusion criteria for hemophilia participants:&#xD;
&#xD;
          -  Clinically significant endocrine, gastrointestinal (including peptic ulcer disease),&#xD;
             cardiovascular, hematological (except factor IX deficiency), immunological, renal,&#xD;
             respiratory, neurological or genitourinary abnormalities or diseases&#xD;
&#xD;
          -  History of malignant neoplastic disease, with the exception of adequately treated&#xD;
             non-melanomatous skin carcinoma or other malignancies that have been successfully&#xD;
             treated ≥10 years prior to the study&#xD;
&#xD;
          -  Consumption of excessive amounts of alcohol, defined as greater than 3 glasses of&#xD;
             alcoholic beverages (1 glass is approximately equivalent to: beer [284 mL/10 ounces],&#xD;
             wine [125 mL/4 ounces], or distilled spirits [25 mL/1 ounce]) within 24 hours prior to&#xD;
             study procedures&#xD;
&#xD;
          -  Major surgery, donation or loss of 1 unit of blood (approximately 500 mL) or&#xD;
             participation in another investigational study within 7 days prior to the date of&#xD;
             study procedures&#xD;
&#xD;
          -  Current regular user (including illicit drugs or has a history of drug [including&#xD;
             alcohol] abuse within approximately 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Belgium</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>June 3, 2011</study_first_submitted>
  <study_first_submitted_qc>June 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2011</study_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophilia B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

